Codexis Inc. logo

Codexis Inc.

CDXS | NASDAQ
Chart Builder DCF Calculator
$1.38
+$0.02 (+1.47%)
At close: Sep 21, 2026, 4:00 PM ET
$1.40
+$0.02 (+1.45%)
Pre-market: Sep 22, 2026, 5:17 AM ET

Company Profile

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.

Key Executives

Name Position
Alison Moore President, Chief Executive Officer & Director
Georgia L. Erbez Chief Financial Officer & Chief Business Officer
Britton Jimenez Senior Vice President of Sales & Marketing
John Schiffhauer Senior Vice President of Intellectual Property
Karen Frechou-Armijo Senior Vice President & Head of Human Resources
Senator Byron L. Dorgan Consultant
Stefan Lutz Chief Scientific Officer

Latest SEC Filings

Date Type Title
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 10-Q Quarterly Report
Aug 11, 2026 8-K Current Report
Jul 29, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 27, 2026 8-K Current Report
Jul 24, 2026 424B5 Filing
Jul 23, 2026 424B5 Filing
Jul 23, 2026 8-K Current Report
Jul 20, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 22, 2026 8-K Current Report
View All SEC Filings
Codexis Inc.
Codexis Inc. logo
Country United States
IPO Date Apr 21, 2010
Industry Biotechnology
Sector Healthcare
Employees 146
CEO Alison Moore

Contact Details

200 Penobscot Drive Redwood City, California 94063 United States

Stock Details

Ticker Symbol CDXS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001200375
CUSIP Number 192005106
ISIN Number US1920051067
SIC Code 2860

© 2026 bestshares.com. All rights reserved.